It was shown that FCHSD2 is a predictor of outcome in AML patients and that the determination of FCHSD2 expression at the time of diagnosis could help to predict the responses of AML patients to chemotherapy [33]. Here, FCHSD2 is linked to acute myeloid leukemia.